GlassScriptPhysician profile
Andrew L Wade
NPI 1710070685
$2,546.33
in general payments reported to CMS, 2019-2025
25 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $229 · 2021: $366 · 2022: $401 · 2023: $203 · 2024: $349 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.65 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $419.01 | 2019-2023 | Yupelri |
| Glaxosmithkline, LLC. | $352.24 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Ani Pharmaceuticals, INC. | $323.55 | 2022-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $297.07 | 2019-2023 | Tezspire |
| Mallinckrodt Hospital Products INC. | $200.76 | 2020-2025 | Acthar |
| Grifols USA, LLC | $165.54 | 2019-2024 | Prolastin-C Liquid |
| Abbott Laboratories | $139.65 | 2025 | 2nd Gen Centrimag Primary Console, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.21 | 2019-2025 | |
| Baxter Healthcare | $67.38 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Sunovion Pharmaceuticals INC. | $45.60 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $44.87 | 2022 | |
| Viatris Specialty LLC | $33.27 | 2025 | Yupelri |
| Genzyme Corporation | $33.19 | 2021 | |
| Mallinckrodt Enterprises LLC | $32.74 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $20.36 | 2025 | Omnipod |
| Paratek Pharmaceuticals, INC. | $18.51 | 2025 | Xhance, Nuzyra |
| Insmed, INC. | $16.56 | 2025 | Arikayce |
| Nabriva Therapeutics, Plc | $16.24 | 2022 | |
| Genentech USA, INC. | $15.86 | 2019 | |
| Advanced Respiratory, INC | $15.02 | 2021 | |
| Inogen, INC. | $14.38 | 2025 | |
| Tactile Systems Technology INC | $13.44 | 2024 | Entre Plus, Flexitouch Plus |
| Regeneron Healthcare Solutions, INC. | $12.59 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.